Entry

D11358                      Drug

Name

Tagraxofusp (USAN/INN);
Tagraxofusp-erzs;
Elzonris (TN)

Product

ELZONRIS (Stemline Therapeutics)

Formula

C2553H4026N692O798S16

Exact mass

57659.1258

Mol weight

57694.4811

Sequence

MGADDVVDSS KSFVMENFSS YHGTKPGYVD SIQKGIQKPK SGTQGNYDDD WKGFYSTDNK
YDAAGYSVDN ENPLSGKAGG VVKVTYPGLT KVLALKVDNA ETIKKELGLS LTEPLMEQVG
TEEFIKRFGD GASRVVLSLP FAEGSSSVEY INNWEQAKAL SVELEINFET RGKRGQDAMY
EYMAQACAGN RVRRSVGSSL SCINLDWDVI RDKTKTKIES LKEHGPIKNK MSESPNKTVS
EEKAKQYLEE FHQTALEHPE LSELKTVTGT NPVFAGANYA AWAVNVAQVI DSETADNLEK
TTAALSILPG IGSVMGIADG AVHHNTEEIV AQSIALSSLM VAQAIPLVGE LVDIGFAAYN
FVESIINLFQ VVHNSYNRPA YSPGHKTRPH MAPMTQTTSL KTSWVNCSNM IDEIITHLKQ
PPLPLLDFNN LNGEDQDILM ENNLRRPNLE AFNRAVKSLQ NASAIESILK NLLPCLPLAT
AAPTRHPIHI KDGDWNEFRR KLTFYLKTLE NAQAQQTTLS LAIF
(Disulfide bridge: 187-202, 407-475)

Type

Peptide

Remark

ATC code:

L01XX67

Product:

D11358<US>

Efficacy

Antineoplastic, Immunotoxin

Comment

Diphteria toxin fusion protein with peptide and interleukin 3
Treatment of blastic plasmacytoid dendritic cell neoplasm (CD123-directed)

Target

IL3RA (CD123) [HSA:3563] [KO:K04737]

Pathway

hsa04210

Apoptosis

hsa04640

Hematopoietic cell lineage

hsa05200

Pathways in cancer

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XX Other antineoplastic agents
     L01XX67 Tagraxofusp
      D11358  Tagraxofusp (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
  Antineoplastics, Other
   Tagraxofusp
    D11358  Tagraxofusp (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
  Cytokine receptors
   Interleukin receptors
    IL3RA (CD123)
     D11358  Tagraxofusp (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11358
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11358
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11358

Other DBs

CAS:	2055491-00-2

PubChem:

384585336